CoPlavix Dosage/Direction for Use

Adults and Elderly: CoPlavix should be given as a single daily dose.
CoPlavix is used following an initial loading dose of clopidogrel 300 mg in combination with aspirin in patients with acute coronary syndrome: Patients with Non-ST Segment Elevation Acute Coronary Syndrome (Unstable Angina or Non-Q-Wave Myocardial Infarction): Treatment should be initiated with a single loading dose of clopidogrel 300 mg plus the appropriate dose of aspirin. Four (4) tablets of CoPlavix (clopidogrel 75 mg/aspirin 75 mg) can alternatively be given if the aspirin dosing is deemed appropriate. Long term daily treatment should be continued with one CoPlavix tablet (75 mg/75 mg or 75 mg/100 mg) once daily taken with adequate water. The optimal duration of treatment has not been formally established. Clinical trial data support use up to 12 months and the maximum benefit was seen at 3 months (see Pharmacology: Pharmacodynamics under Actions). If the use of CoPlavix is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
Patients with ST Segment Elevation Acute Myocardial Infarction: Treatment should be initiated with or without a loading dose of clopidogrel 300 mg in combination with aspirin and with or without thrombolytics. Therapy should be started as early as possible after symptoms start and continued for at least 4 weeks. The benefit of the combination of clopidogrel with ASA >4 weeks has not been studied in this setting (see Pharmacology: Pharmacodynamics under Actions).
Daily treatment should continue with one CoPlavix tablet (75 mg/75 mg or 75 mg/100 mg) once daily taken with adequate water.
Atrial Fibrillation: Clopidogrel + ASA should be given as a single daily 75 mg/75 mg or 75 mg/100 mg dose. (See Pharmacology: Pharmacodynamics and Clinical Efficacy/Clinical Studies under Actions.)
No dosage adjustment is necessary for maintenance therapy in elderly patients.
Missed Dose: Within <12 hrs after regular scheduled time, patients should take the dose immediately and then take the next dose at the regular scheduled time.
For >12 hrs: Patients should take the next dose at the regular scheduled time and should not double the dose.
Pharmacogenetics: CYP2C19 poor metaboliser status is associated with diminished antiplatelet response to clopidogrel. A higher dose regimen (600-mg loading dose followed by 150 mg once daily) in poor metabolisers increases antiplatelet response (see Pharmacology: Pharmacokinetics and Pharmacogenetics under Actions). Consider the use of higher clopidogrel doses in patients who are poor CYP2C19 metabolisers. An appropriate dose regimen for this patient population has not been established in clinical outcome trials.
Administration: CoPlavix is for oral use. It may be given with or without food.